Latest & greatest articles for type 2 diabetes

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on type 2 diabetes or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on type 2 diabetes and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for type 2 diabetes

2041. Effect of intensive therapy on early macrovascular disease in young individuals with type 1 diabetes: a systematic review and meta-analysis

the effect of intensive insulin therapy (IIT) in type 1 diabetes on macrovascular complications. Searching MEDLINE was searched from January 1966 to January 1996. Citation Index, personal files, and bibliographies of all retrieved articles were used to identify further articles. There were no restrictions on language of publication. Study selection Study designs of evaluations included in the review Randomised controlled trials (RCTs) of 2 years or more duration. Crossover trials were also considered (...) but none of the trials lasted 2 years or more. Specific interventions included in the review Intensive insulin therapy (IIT) through multiple daily injections (3-4/day) of insulin or subcutaneous insulin pump, and conventional therapy (CT), defined as one or two insulin injections per day. Participants included in the review Adults (18-50 yrs) with type 1 diabetes. Studies involving type 1 diabetic patients after renal transplant were excluded. Outcomes assessed in the review The primary outcome

1999 DARE.

2042. Troglitazone: a review of its use in the management of type 2 diabetes mellitus

Troglitazone: a review of its use in the management of type 2 diabetes mellitus Troglitazone: a review of its use in the management of type 2 diabetes mellitus Troglitazone: a review of its use in the management of type 2 diabetes mellitus Plosker G L, Faulds D Authors' objectives To review the use of troglitazone in the management of type 2 diabetes mellitus. The review included epidemiological, pharmacological and tolerability data in addition to effectiveness data. Searching AdisBase (...) ) or insulin. Comparators included other oral antidiabetic drugs and placebo groups. Participants included in the review Patients with type 2 diabetes mellitus or impaired glucose tolerance. Impaired glucose tolerance was typically defined as fasting plasma or serum glucose (FPG or FSG) levels between 7 and 15mmol/L (126 and 270mg/dl). Most of the trials reported in the review involved patients (aged 40-75yrs) with type 2 diabetes mellitus that was inadequately controlled by diet alone (or by diet

1999 DARE.

2043. A prospective trial of risk factors for sulfonylurea-induced hypoglycemia in type 2 diabetes mellitus. (Abstract)

A prospective trial of risk factors for sulfonylurea-induced hypoglycemia in type 2 diabetes mellitus. Retrospective studies have identified oral sulfonylureas, age, and fasting as major risk factors for hypoglycemia in patients with type 2 diabetes. Sulfonylureas may be withheld from elderly patients out of concern for hypoglycemia.To evaluate the hypoglycemic effects of maximum doses of once-daily second-generation sulfonylureas administered to fasting elderly patients.A prospective (...) , randomized, double-blind clinical trial.The University of New Mexico General Clinical Research Center.Fifty-two sulfonylurea-treated subjects with type 2 diabetes with a mean (SD) age of 65.1 (5.7) years.Subjects were randomly assigned to glyburide or glipizide gastrointestinal therapeutic system (GITS). Each subject participated in three 23-hour fasting studies after the sequential administration of 1 week of placebo and 1 week of 10 mg and 1 week of 20 mg of the assigned sulfonylurea.Occurrence

1998 JAMA Controlled trial quality: uncertain

2044. Effect of troglitazone in insulin-treated patients with type II diabetes mellitus. Troglitazone and Exogenous Insulin Study Group. (Abstract)

Effect of troglitazone in insulin-treated patients with type II diabetes mellitus. Troglitazone and Exogenous Insulin Study Group. Troglitazone is a new oral antidiabetic drug that increases the sensitivity of peripheral tissues to insulin. It may therefore increase the efficacy of exogenous insulin in patients with insulin-resistant diabetes mellitus.We studied the effect of troglitazone or placebo in 350 patients with poorly controlled non-insulin-dependent (type 2) diabetes mellitus (...) in patients with type 2 diabetes mellitus.

1998 NEJM Controlled trial quality: uncertain

2045. Efficacy and metabolic effects of metformin and troglitazone in type II diabetes mellitus. (Abstract)

Efficacy and metabolic effects of metformin and troglitazone in type II diabetes mellitus. Combination therapy is logical for patients with non-insulin-dependent (type 2) diabetes mellitus, because they often have poor responses to single-drug therapy. We studied the efficacy and physiologic effects of metformin and troglitazone alone and in combination in patients with type 2 diabetes.We randomly assigned 29 patients to receive either metformin or troglitazone for three months, after which (...) and additive beneficial effects on glycemic control in patients with type 2 diabetes. Metformin acts primarily by decreasing endogenous glucose production, and troglitazone by increasing the rate of peripheral glucose disposal.

1998 NEJM Controlled trial quality: uncertain

2046. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group. Full Text available with Trip Pro

Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group. To determine whether tight control of blood pressure prevents macrovascular and microvascular complications in patients with type 2 diabetes.Randomised controlled trial comparing tight control of blood pressure aiming at a blood pressure of <150/85 mm Hg (with the use of an angiotensin converting enzyme inhibitor captopril or a beta blocker (...) atenolol as main treatment) with less tight control aiming at a blood pressure of <180/105 mm Hg.20 hospital based clinics in England, Scotland, and Northern Ireland.1148 hypertensive patients with type 2 diabetes (mean age 56, mean blood pressure at entry 160/94 mm Hg); 758 patients were allocated to tight control of blood pressure and 390 patients to less tight control with a median follow up of 8.4 years.Predefined clinical end points, fatal and non-fatal, related to diabetes, deaths related

1998 BMJ Controlled trial quality: predicted high

2047. Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39. UK Prospective Diabetes Study Group. Full Text available with Trip Pro

Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39. UK Prospective Diabetes Study Group. To determine whether tight control of blood pressure with either a beta blocker or an angiotensin converting enzyme inhibitor has a specific advantage or disadvantage in preventing the macrovascular and microvascular complications of type 2 diabetes.Randomised controlled trial comparing an angiotensin converting enzyme inhibitor (...) (captopril) with a beta blocker (atenolol) in patients with type 2 diabetes aiming at a blood pressure of <150/<85 mm Hg.20 hospital based clinics in England, Scotland, and Northern Ireland.1148 hypertensive patients with type 2 diabetes (mean age 56 years, mean blood pressure 160/94 mm Hg). Of the 758 patients allocated to tight control of blood pressure, 400 were allocated to captopril and 358 to atenolol. 390 patients were allocated to less tight control of blood pressure.Predefined clinical end

1998 BMJ Controlled trial quality: uncertain

2048. Cost effectiveness analysis of improved blood pressure control in hypertensive patients with type 2 diabetes: UKPDS 40. UK Prospective Diabetes Study Group. Full Text available with Trip Pro

Cost effectiveness analysis of improved blood pressure control in hypertensive patients with type 2 diabetes: UKPDS 40. UK Prospective Diabetes Study Group. To estimate the economic efficiency of tight blood pressure control, with angiotensin converting enzyme inhibitors or beta blockers, compared with less tight control in hypertensive patients with type 2 diabetes.Cost effectiveness analysis incorporating within trial analysis and estimation of impact on life expectancy through use (...) of the within trial hazards of reaching a defined clinical end point. Use of resources driven by trial protocol and use of resources in standard clinical practice were both considered.20 hospital based clinics in England, Scotland, and Northern Ireland.1148 hypertensive patients with type 2 diabetes from UK prospective diabetes study randomised to tight control of blood pressure (n=758) or less tight control (n=390).Cost effectiveness ratios based on (a) use of healthcare resources associated with tight

1998 BMJ Controlled trial quality: uncertain

2049. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. (Abstract)

Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Improved blood-glucose control decreases the progression of diabetic microvascular disease, but the effect on macrovascular complications is unknown. There is concern that sulphonylureas may increase cardiovascular mortality in patients with type 2 diabetes and that high insulin (...) concentrations may enhance atheroma formation. We compared the effects of intensive blood-glucose control with either sulphonylurea or insulin and conventional treatment on the risk of microvascular and macrovascular complications in patients with type 2 diabetes in a randomised controlled trial.3867 newly diagnosed patients with type 2 diabetes, median age 54 years (IQR 48-60 years), who after 3 months' diet treatment had a mean of two fasting plasma glucose (FPG) concentrations of 6.1-15.0 mmol/L were

1998 Lancet Controlled trial quality: predicted high

2050. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group. (Abstract)

Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group. In patients with type 2 diabetes, intensive blood-glucose control with insulin or sulphonylurea therapy decreases progression of microvascular disease and may also reduce the risk of heart attacks. This study investigated whether intensive glucose control with metformin has any specific advantage or disadvantage.Of 4075 (...) patients recruited to UKPDS in 15 centres, 1704 overweight (>120% ideal bodyweight) patients with newly diagnosed type 2 diabetes, mean age 53 years, had raised fasting plasma glucose (FPG; 6.1-15.0 mmol/L) without hyperglycaemic symptoms after 3 months' initial diet. 753 were included in a randomised controlled trial, median duration 10.7 years, of conventional policy, primarily with diet alone (n=411) versus intensive blood-glucose control policy with metformin, aiming for FPG below 6 mmol/L (n=342

1998 Lancet Controlled trial quality: predicted high

2051. Effect of excessive weight gain with intensive therapy of type 1 diabetes on lipid levels and blood pressure: results from the DCCT. Diabetes Control and Complications Trial. Full Text available with Trip Pro

Effect of excessive weight gain with intensive therapy of type 1 diabetes on lipid levels and blood pressure: results from the DCCT. Diabetes Control and Complications Trial. Intensive treatment of type 1 diabetes results in greater weight gain than conventional treatment.To determine the effect of this weight gain on lipid levels and blood pressure.Randomized controlled trial; ancillary study of the Diabetes Control and Complications Trial (DCCT).Twenty-one clinical centers.The 1168 subjects (...) enrolled in DCCT with type 1 diabetes who were aged 18 years or older at baseline.Randomized to receive either intensive (n = 586) or conventional (n = 582) diabetes treatment with a mean follow-up of 6.1 years.Plasma lipid levels and blood pressure in each treatment group categorized by quartile of weight gain.With intensive treatment, subjects in the fourth quartile of weight gain had the highest body mass index (BMI) (a measure of weight adjusted for height), blood pressure, and levels

1998 JAMA Controlled trial quality: uncertain

2052. Effect of lisinopril on progression of retinopathy in normotensive people with type 1 diabetes. The EUCLID Study Group. EURODIAB Controlled Trial of Lisinopril in Insulin-Dependent Diabetes Mellitus. (Abstract)

Effect of lisinopril on progression of retinopathy in normotensive people with type 1 diabetes. The EUCLID Study Group. EURODIAB Controlled Trial of Lisinopril in Insulin-Dependent Diabetes Mellitus. Retinopathy commonly occurs in people with type 1 diabetes. Strict glycaemic control can decrease development and progression of retinopathy only partially. Blood pressure is also a risk factor for microvascular complications. Antihypertensive therapy, especially with inhibitors of angiotensin (...) -converting enzyme (ACE), can slow progression of nephropathy, but the effects on retinopathy have not been established. We investigated the effect of lisinopril on retinopathy in type 1 diabetes.As part of a 2-year randomised double-blind placebo-controlled trial, we took retinal photographs at baseline and follow-up (24 months) in patients aged 20-59 in 15 European centres. Patients were not hypertensive, and were normoalbuminuric (85%) or microalbuminuric. Retinopathy was classified from photographs

1998 Lancet Controlled trial quality: predicted high

2053. Health economic benefits and quality of life during improved glycemic control in patients with type 2 diabetes mellitus: a randomized, controlled, double-blind trial. (Abstract)

Health economic benefits and quality of life during improved glycemic control in patients with type 2 diabetes mellitus: a randomized, controlled, double-blind trial. Although the long-term health benefits of good glycemic control in patients with diabetes are well documented, shorter-term quality of life (QOL) and economic savings generally have been reported to be minimal or absent.To examine short-term outcomes of glycemic control in type 2 diabetes mellitus (DM).Double-blind, randomized (...) <.001), fewer bed-days (losses = $1539 vs $1843 per 1000 person-days; P=.05), and fewer restricted-activity days (losses = $2660 vs $4275 per 1000 person-days; P=.01).Improved glycemic control of type 2 DM is associated with substantial short-term symptomatic, QOL, and health economic benefits.

1998 JAMA Controlled trial quality: predicted high

2054. Evaluation of the potential clinical and economic effects of bodyweight stabilisation with acarbose in patients with type 2 diabetes mellitus: a decision-analytical approach

Evaluation of the potential clinical and economic effects of bodyweight stabilisation with acarbose in patients with type 2 diabetes mellitus: a decision-analytical approach Evaluation of the potential clinical and economic effects of bodyweight stabilisation with acarbose in patients with type 2 diabetes mellitus: a decision-analytical approach Evaluation of the potential clinical and economic effects of bodyweight stabilisation with acarbose in patients with type 2 diabetes mellitus (...) : a decision-analytical approach Banz K, Dinkel R, Hanefeld M, Schwanebeck U Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology Acarbose or glibenclamide therapy in patients with type 2 (non-insulin-dependent) diabetes mellitus. Type

1998 NHS Economic Evaluation Database.

2055. Meta-analysis of the effect of insulin lispro on severe hypoglycemia in patients with type 1 diabetes

diabetic patients. Searching The Eli Lilly database was searched. Study selection Study designs of evaluations included in the review Randomised controlled trials (RCTs) comparing the incidence of severe hypoglycaemia in type 1 diabetics during insulin lispro therapy and during soluble insulin therapy. The trials were included if they measured hypoglycaemia using a standard hypoglycaemia questionnaire, they enrolled at least 50 patients, and were of at least 2 months' duration. Both parallel (...) adjusted, based on glucose self-monitoring and the metabolic needs of the patient. The glycaemic targets were fasting blood glucose values of less than 7.8 mmol/L without hypoglycaemia, and maintenance of 2-hour post-prandial glucose values of less than 10 mmol/L. Participants included in the review Type I diabetes. The participants included adults, newly diagnosed adults, and adolescents with type I diabetes. Patients with a history of recurrent severe hypoglycaemia were excluded. Outcomes assessed

1998 DARE.

2056. Glimepiride: role of a new sulfonylurea in the treatment of type 2 diabetes mellitus

Glimepiride: role of a new sulfonylurea in the treatment of type 2 diabetes mellitus Glimepiride: role of a new sulfonylurea in the treatment of type 2 diabetes mellitus Glimepiride: role of a new sulfonylurea in the treatment of type 2 diabetes mellitus Campbell R K Authors' objectives To assess the efficacy and safety of glimepiride with and without insulin in the treatment of type 2 diabetes mellitus. Searching A MEDLINE database search (January 1985 to April 1997) was performed for English (...) trials were excluded. Specific interventions included in the review Glimepiride (1 to 16 mg total daily dose, usually given once daily for a period of 8 to 52 weeks), other sulfonylureas (glipizide and glyburide), insulin and placebo. Participants included in the review Male and female patients between the ages of 30 and 80 years with type 2 diabetes mellitus uncontrolled by diet and exercise which was confirmed during a single-blind, placebo-controlled washout period. Outcomes assessed in the review

1998 DARE.

2057. The cost-effectiveness of screening for type 2 diabetes

The cost-effectiveness of screening for type 2 diabetes The cost-effectiveness of screening for type 2 diabetes The cost-effectiveness of screening for type 2 diabetes CDC Diabetes Cost-Effectiveness Study Group Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study (...) and the conclusions drawn. Health technology Screening for type 2 diabetes mellitus using a fasting plasma glucose test (FPGT) confirmed by an oral glucose tolerance test (OGTT)(for persons testing positive to the first test). Type of intervention Screening. Economic study type Cost-effectiveness analysis and cost-utility analysis. Study population A hypothetical population, aged 25 years and above, modelled on the general US population without diagnosed diabetes and of whom a percentage (forming a cohort

1998 NHS Economic Evaluation Database.

2058. Initiating insulin treatment in insulin-requiring type 2 diabetic patients: comparative efficiency and cost of outpatient and inpatient management

Initiating insulin treatment in insulin-requiring type 2 diabetic patients: comparative efficiency and cost of outpatient and inpatient management Initiating insulin treatment in insulin-requiring type 2 diabetic patients: comparative efficiency and cost of outpatient and inpatient management Initiating insulin treatment in insulin-requiring type 2 diabetic patients: comparative efficiency and cost of outpatient and inpatient management Penfornis A, Millot L Record Status This is a critical (...) abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology Outpatient approach to initiating insulin therapy in insulin-requiring Type 2 diabetic patients. Type of intervention Treatment. Economic study type Cost-effectiveness analysis. Study population Type 2 diabetic patients

1998 NHS Economic Evaluation Database.

2059. Cost effectiveness analysis of improved blood pressure control in hypertensive patients with type 2 diabetes: UKPDS 40

Cost effectiveness analysis of improved blood pressure control in hypertensive patients with type 2 diabetes: UKPDS 40 Cost effectiveness analysis of improved blood pressure control in hypertensive patients with type 2 diabetes: UKPDS 40 Cost effectiveness analysis of improved blood pressure control in hypertensive patients with type 2 diabetes: UKPDS 40 UK Prospective Diabetes Study Group Record Status This is a critical abstract of an economic evaluation that meets the criteria for inclusion (...) on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology Blood pressure control in hypertensive patients with type 2 diabetes. Type of intervention Secondary prevention. Economic study type Cost-effectiveness analysis. Study population Hypertensive patients with type 2 diabetes. The mean (SD) age of patients was 56.4(8.1) years. Setting

1998 NHS Economic Evaluation Database.

2060. Modelling and costing the consequences of using an ACE inhibitor to slow the progression of renal failure in type I diabetic patients

Modelling and costing the consequences of using an ACE inhibitor to slow the progression of renal failure in type I diabetic patients Modelling and costing the consequences of using an ACE inhibitor to slow the progression of renal failure in type I diabetic patients Modelling and costing the consequences of using an ACE inhibitor to slow the progression of renal failure in type I diabetic patients Hendry B M, Viberti G C, Hummel S, Bagust A, Piercy J Record Status This is a critical abstract (...) of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn. Health technology Using an angiotensin-converting enzyme (ACE)inhibitor, captopril (25 mg, 3 times a day) to slow progression of renal failure in diabetic patients. Type of intervention Treatment. Economic study type Cost-effectiveness analysis. Study

1997 NHS Economic Evaluation Database.